Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (“BioSig” or the “Company”), which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM), today announced the pricing of its previously announced underwritten public offering of 3,852,149 shares of common stock at a public offering price of $3.90 per share. The offering is expected to close on or around August 15, 2025 subject to customary closing conditions. The gross proceeds from the offering, before deducting underwriter discounts and commissions and other estimated offering expenses are expected to be approximately $15,023,381.10. BioSig intends to use the net proceeds from the offering to purchase gold bullion in accordance with its investment policy, for working capital and for general corporate purposes.
Related Questions
What dilution impact will the issuance of 3,852,149 new shares have on existing shareholders' ownership percentage and EPS?
What is the pricing premium/discount relative to recent trading prices and the company's historical offering prices?
How does the $3.90 per share price compare to the current market price and implied valuation multiples (P/E, P/B, etc.)?
What are the terms and conditions of the underwriting agreement, including any over‑allotment options or lock‑up periods?
How does the planned use of proceeds (gold bullion purchase, working capital, general corporate purposes) align with BioSig’s strategic objectives and risk profile?
What is the expected timeline for the purchase of gold bullion and how will that affect the company's asset composition and balance sheet risk?
How might the gold purchase policy affect BioSig’s exposure to commodity price volatility and hedging requirements?
Will the new capital enable BioSig to accelerate product development, acquisitions, or other growth initiatives?
What impact, if any, will the offering have on BioSig's credit facilities, covenant compliance, and future financing flexibility?
How does this offering compare to recent capital raises by peer companies in the biotech/medical device sector?
What is the market’s reaction to the news (trading volume, price movement) and what are the short‑term price expectations?
Are there any regulatory or listing implications from the merger with Streamex that could affect share liquidity or corporate governance?
What are the potential tax implications for the company and shareholders from the capital raise and subsequent gold purchases?
How might the proceeds be allocated between gold purchases and working capital, and what are the projected returns or cost of capital for each use?
How will the $15 million capital raise affect BioSig's cash balance and liquidity ratios?